Metabolic Disorders Stocks
Biopharmaceutical and medical technology firms in this sector develop therapeutic interventions for chronic endocrine and metabolic imbalances, specifically targeting diabetes, obesity, and rare hormonal dysfunctions. Revenue models center on high-volume maintenance medications, specialized delivery systems, and breakthrough gene therapies aimed at regulating systemic biological pathways.
As of Oct 23, 2026, Metabolic Disorders has 79 US-listed companies worth $1.8T combined. The median member moved +1.0% over the past week; BHVN led among the 25 largest at +28.8% and CORT trailed at -22.1%.
Companies in Metabolic Disorders
- LLY – Eli Lilly and Company, $1.1T
- AZN – AstraZeneca PLC, $266B
- NVO – Novo Nordisk A/S, $172B
- DXCM – DexCom Inc, $29.6B
- MEDP – Medpace Holdings Inc, $18.3B
- ASND – Ascendis Pharma AS, $16B
- CORT – Corcept Therapeutics Incorporated, $11.6B
- BMRN – Biomarin Pharmaceutical Inc, $10.8B
- PODD – Insulet Corporation, $10.3B
- MDGL – Madrigal Pharmaceuticals Inc, $10B
- ARWR – Arrowhead Pharmaceuticals Inc, $8.2B
- RYTM – Rhythm Pharmaceuticals Inc, $6.3B
- BLTE – Belite Bio Inc ADR, $5.8B
- PTCT – PTC Therapeutics Inc, $5.3B
- SRRK – Scholar Rock Holding Corp, $5.1B
- TVTX – Travere Therapeutics Inc, $4.9B
- VKTX – Viking Therapeutics Inc, $3.3B
- MBX – MBX Biosciences, Inc. Common Stock, $2.5B
- AGIO – Agios Pharm, $2.2B
- XERS – Xeris Pharmaceuticals Inc, $2B
- MLYS – Mineralys Therapeutics, Inc. Common Stock, $1.9B
- SEPN – Septerna, Inc. Common Stock, $1.8B
- BHVN – Biohaven Ltd., $1.8B
- KLRA – Kailera Therapeutics, Inc. Common Stock, $1.7B
- ETON – Eton Pharmaceuticals Inc, $1.6B
- GPCR – Structure Therapeutics Inc. American Depositary Shares, $1.6B
- RARE – Ultragenyx, $1.6B
- MAZE – Maze Therapeutics, Inc. Common Stock, $1.5B
- MNKD – MannKind Corp, $1.2B
- TNDM – Tandem Diabetes Care Inc, $1.1B
- OMDA – Omada Health, Inc. Common Stock, $1.1B
- BBNX – Beta Bionics, Inc. Common Stock, $1B
- LXRX – Lexicon Pharmaceuticals Inc, $783M
- IVA – Inventiva Sa, $770M
- FTH – Faeth Therapeutics, Inc., $733M
- ZVRA – Zevra Therapeutics Inc., $676M
- SGMT – Sagimet Biosciences Inc. Series A Common Stock, $633M
- ALT – Altimmune Inc, $595M
- SENS – Senseonics Holdings, Inc. Common Stock, $484M
- RZLT – Rezolute Inc, $396M
- EMBC – Embecta Corp, $389M
- GALT – Galectin Therapeutics Inc, $374M
- BIOA – BioAge Labs, Inc, $222M
- VOGX – Vogenx Inc Common Stock, $216M
- ORMP – Oramed Pharmaceuticals Inc, $171M
- MED – MEDIFAST INC, $133M
- VTVT – vTv Therapeutics Inc, $119M
- COYA – Coya Therapeutics, Inc. Common Stock, $116M
- AARD – Aardvark Therapeutics, Inc. Common Stock, $104M
- VANI – Vivani Medical Inc., $104M
- RFL – Rafael Holdings, Inc., $74.4M
- IBIO – iBio, Inc. Common Stock, $72.3M
- BMEA – Biomea Fusion Inc, $50M
- VERU – Veru Inc, $41.9M
- IBO – Impact BioMedical, Inc., $34M
- ALGS – Aligos Therapeutics Inc, $33.3M
- GUTS – Fractyl Health, Inc. Common Stock, $20.6M
- BPTSY – Biophytis S.A., $17.5M
- LPCN – Lipocine Inc, $16.9M
- NCEL – NewcelX Ltd., $16.5M
- QNTM – Quantum BioPharma Ltd., $14.6M
- SYBX – Synlogic Inc, $13M
- MTVA – MetaVia Inc., $9.6M
- NDRA – ENDRA Life Sciences Inc, $9.1M
- TCRT – Alaunos Therapeutics Inc, $7.7M
- SKYE – Skye Bioscience, Inc. Common Stock, $7.2M
- GELS – Gelteq Limited Ordinary Shares, $5.9M
- CANF – Can Fite Biopharma Ltd ADR, $5.9M
- TRIB – Trinity Biotech plc, $5.5M
- LEXX – Lexaria Bioscience Corp, $5.5M
- GLMD – Galmed Pharmaceuticals Ltd, $4.9M
- BRTX – BioRestorative Therapies Inc, $3.1M
- XRTX – XORTX Therapeutics Inc, $2.3M
- PTIX – Protagenic Therapeutics, $1.4M
- GCTK – GlucoTrack Inc, $662,830
- ZVSA – ZyVersa Therapeutics Inc., $647,673
- PFSA – Profusa, Inc. Common Stock, $563,917
- ALUR – Allurion Technologies, Inc., $342,107
- KLDO – Kaleido Biosciences Inc, $4,262